Finance

Lists
012790:KOSDAQ
Sinil Pharmaceutical Co Ltd
â‚©6,400.00
-0.16%
(-10.00) 1D
Oct 21, 11:24:48 AM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 012790...
Open
â‚©6,430
High
â‚©6,430
Low
â‚©6,370
Mkt. cap
76.71B
Avg. vol.
17.42K
Volume
1.52K
Dividend
2.97%
Quarterly dividend
â‚©48
Ex-dividend date
Dec 29, 2025
P/E ratio
11.54
52-wk high
â‚©6,820
52-wk low
â‚©4,820
EPS
â‚©555
Shares outstanding
11.99M
No. of employees
414
Open
â‚©6,430
High
â‚©6,430
Low
â‚©6,370
Mkt. cap
76.71B
Avg. vol.
17.42K
Volume
1.52K
Dividend
2.97%
Quarterly dividend
â‚©48
Ex-dividend date
Dec 29, 2025
P/E ratio
11.54
52-wk high
â‚©6,820
52-wk low
â‚©4,820
EPS
â‚©555
Shares outstanding
11.99M
No. of employees
414
News stories
From web sources and news partners
About Sinil Pharmaceutical Co Ltd
CEO-
Employees414
Founded1971
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
20.62B
21.14B
20.87B
24.20B
Cost of goods sold
11.78B
13.94B
10.89B
13.20B
Cost of revenue
11.78B
13.94B
10.89B
13.20B
Research and development expenses
-
680.00M
1.03B
656.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.17B
6.68B
7.48B
7.97B
Operating expense
6.18B
7.62B
8.65B
8.74B
Total operating expenses
17.95B
21.56B
19.54B
21.94B
Operating income
2.67B
-424.33M
1.33B
2.26B
Other non operating income
394.71M
-106.29M
97.07M
63.62M
EBT including unusual items
3.06B
-156.10M
1.48B
2.64B
EBT excluding unusual items
3.06B
-181.17M
1.77B
2.64B
Income tax expense
457.51M
-289.00M
43.57M
402.71M
Effective tax rate
14.93%
185.14%
2.94%
15.23%
Other operating expenses
-
106.99M
73.72M
20.56M
Net income
2.61B
132.90M
1.44B
2.24B
Net profit margin
12.64%
0.63%
6.88%
9.27%
Earnings per share
-
-
-
-
Interest and investment income
-
292.58M
254.05M
267.73M
Interest expense
-
-4.16M
-3.70M
-3.32M
Net interest expenses
-
288.42M
250.36M
264.40M
Depreciation and amortization charges
-
152.49M
66.95M
84.25M
EBITDA
4.24B
1.14B
2.83B
3.81B
Gain or loss from assets sale
-
24.33M
-
192.25M
AI content may include mistakes. Learn more
Google apps